NASDAQ:CTXR   Citius Pharmaceuticals, Inc.
test
Citius Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development and commercialization of critical care products, with a focus on anti-infectives in adjunct cancer care, unique prescription products, and stem cell therapy. It is currently advancing four proprietary product candidates: Mino-Lok, which is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections, Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries, Halo-Lido, a corticosteroid-lidocaine topical formulation that is intended to provide anti-inflammatory and anesthetic relief to people suffering from hemorrhoids, NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory distress syndrome, and I/ONTAK, a protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma (CTCL). The company was founded by Ralph Montrone on January 23, 2007 and is headquartered in Cranford, NJ.
Aviso legal

As informações e publicações não devem ser e não constituem conselhos ou recomendações financeiras, de investimento, de negociação ou de qualquer outro tipo, fornecidas ou endossadas pela TradingView. Leia mais em Termos de uso.